Glympse Bio Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 16

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $23.2M

Glympse Bio General Information

Description

Operator of a diagnostic platform intended to facilitate noninvasive disease monitoring through bio-marker technology. The company's platform utilizes precisely engineered diagnostic agents that interrogate the body for certain disease states and then carry the message to the urine for analysis, enabling physicians to use noninvasive and predictive monitoring of multiple human diseases like certain cancers, blood-clotting diseases, and fibrosis of the liver accurately.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 35 Cambridgepark Drive
  • Suite 100
  • Cambridge, MA 02140
  • United States
+1 (617)
Primary Industry
Biotechnology
Other Industries
Laboratory Services (Healthcare)
Other Healthcare Technology Systems
Acquirer
Vertical(s)
Nanotechnology, Life Sciences
Corporate Office
  • 35 Cambridgepark Drive
  • Suite 100
  • Cambridge, MA 02140
  • United States
+1 (617)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Glympse Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 09-Aug-2023 $23.2M Completed Generating Revenue
5. Later Stage VC (Series B) 17-Dec-2021 Completed Pre-Clinical Trials
4. Later Stage VC (Series B) 15-Jul-2020 Completed Pre-Clinical Trials
3. Grant 01-Jun-2019 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 06-Aug-2018 $26.1M $26.1M Completed Pre-Clinical Trials
1. Grant 01-Jan-2018 $781K Completed Pre-Clinical Trials
To view Glympse Bio’s complete valuation and funding history, request access »

Glympse Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A2
Series A1 10,831,564 $0.000100 8% $2.03 $2.03 1x $2.03 17.91%
To view Glympse Bio’s complete cap table history, request access »

Glympse Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a diagnostic platform intended to facilitate noninvasive disease monitoring through bio-marker technology. T
Biotechnology
Cambridge, MA
16 As of 2023

Los Angeles, CA
 

Abingdon, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Glympse Bio Competitors (2)

One of Glympse Bio’s 2 competitors is Indi Molecular, a Venture Capital-Backed company based in Los Angeles, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Indi Molecular Venture Capital-Backed Los Angeles, CA
Sense Biodetection Formerly VC-backed Abingdon, United Kingdom
You’re viewing 2 of 2 competitors. Get the full list »

Glympse Bio Patents

Glympse Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4211468-A2 Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment Pending 11-Sep-2020
CA-3194956-A1 Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment Pending 11-Sep-2020
EP-4211468-A4 Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment Pending 11-Sep-2020
CA-3181164-A1 Activity sensor controls Pending 24-Apr-2020
EP-4139471-A1 Multi-factor activity monitoring Pending 24-Apr-2020 A61B5/1473
To view Glympse Bio’s complete patent history, request access »

Glympse Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glympse Bio Former Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds
ARCH Venture Partners Venture Capital Minority
Alumni Ventures Venture Capital Minority
Andrew Rapkin Angel (individual) Minority
Ascan Investments Family Office Minority
Aspect Ventures Venture Capital Minority
You’re viewing 5 of 22 investors. Get the full list »

Glympse Bio FAQs

  • When was Glympse Bio founded?

    Glympse Bio was founded in 2015.

  • Where is Glympse Bio headquartered?

    Glympse Bio is headquartered in Cambridge, MA.

  • What is the size of Glympse Bio?

    Glympse Bio has 16 total employees.

  • What industry is Glympse Bio in?

    Glympse Bio’s primary industry is Biotechnology.

  • Is Glympse Bio a private or public company?

    Glympse Bio is a Private company.

  • What is the current valuation of Glympse Bio?

    The current valuation of Glympse Bio is .

  • What is Glympse Bio’s current revenue?

    The current revenue for Glympse Bio is .

  • How much funding has Glympse Bio raised over time?

    Glympse Bio has raised $90.8M.

  • Who are Glympse Bio’s investors?

    ARCH Venture Partners, Alumni Ventures, Andrew Rapkin, Ascan Investments, and Aspect Ventures are 5 of 22 investors who have invested in Glympse Bio.

  • Who are Glympse Bio’s competitors?

    Indi Molecular and Sense Biodetection are competitors of Glympse Bio.

  • When was Glympse Bio acquired?

    Glympse Bio was acquired on 09-Aug-2023.

  • Who acquired Glympse Bio?

    Glympse Bio was acquired by Sunbird Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »